NASDAQ:SABS SAB Biotherapeutics Q4 2024 Earnings Results & Report $2.90 -0.08 (-2.52%) As of 11:36 AM Eastern This is a fair market value price provided by Massive. Learn more. SAB Biotherapeutics missed analyst expectations on both earnings and revenue in its Q4 2024 results, released March 28, 2025. The company reported EPS of -$1.23 versus the -$1.16 consensus estimate, while revenue of $0.05 million fell short of the $0.12 million estimate by $0.07 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 28, 2025TimeBefore Market OpensConference Call DateMarch 30, 2025Conference Call6:00 PM ET SAB Biotherapeutics EPS ResultsActual EPS-$1.23Consensus EPS -$1.16Beat/MissMissed by -$0.07One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersSAB Biotherapeutics Revenue ResultsActual Revenue$0.05 millionExpected Revenue$0.12 millionBeat/MissMissed by -$70.00 thousandYoY Revenue GrowthN/AUpcoming EarningsSAB Biotherapeutics' Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) SAB Biotherapeutics Q4 2024 Earnings FAQ Did SAB Biotherapeutics beat earnings estimates for Q4 2024? SAB Biotherapeutics (NASDAQ:SABS) reported earnings of -$1.23 per share for Q4 2024, missing the consensus estimate of -$1.16. The report was announced on Friday, March 28, 2025. What was SAB Biotherapeutics' revenue for Q4 2024? SAB Biotherapeutics reported revenue of $0.05 million for Q4 2024, against a consensus estimate of $0.12 million. When is SAB Biotherapeutics' next earnings date? SAB Biotherapeutics' next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for SAB Biotherapeutics on the company's earnings history page. SAB Biotherapeutics Earnings HeadlinesContrasting SAB Biotherapeutics (NASDAQ:SABS) and Veracyte (NASDAQ:VCYT)October 6, 2026 | americanbankingnews.comSAB Biotherapeutics, Inc. Announces Presentations Featuring SAB-142 Phase 1 Data At Breakthrough T1D Clinical & Research CongressOctober 1, 2026 | marketscreener.comMFree Ticker: Anthropic's silent partner could soar after record $2 trillion IPOAnthropic's IPO prospectus just leaked, revealing 261 pages tied to a record $2 trillion valuation. Beyond headline backers Amazon and Google, tech analyst Matt McCall has tracked a smaller partner that got in early, before most investors knew Claude existed. Matt calls it a Second IPO opportunity and reveals its name and ticker in a free interview.October 12 at 1:00 AM | Monument Traders Alliance (Ad)SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research CongressOctober 1, 2026 | globenewswire.comSAB Biotherapeutics, Inc. Announces Presentations Of SAB-142 Data At The 62nd Annual Meeting Of The European Association For The Study Of DiabetesSeptember 22, 2026 | marketscreener.comMSAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of DiabetesSeptember 22, 2026 | globenewswire.comSee More SAB Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like SAB Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SAB Biotherapeutics and other key companies, straight to your email. Email Address About SAB BiotherapeuticsSAB Biotherapeutics (NASDAQ:SABS) is a clinical-stage biotechnology company focused on developing antibody-based medicines for infectious diseases, immune disorders and other serious health conditions. The company’s approach is designed to produce fully human polyclonal antibodies that can recognize and neutralize multiple targets associated with a disease. SAB’s technology platform, known as DiversitAb, uses genetically engineered cattle with human immune-system components to generate human antibodies. The resulting antibody preparations are intended to support the development of therapeutics and potentially other medical products. The company has conducted development work on candidates including SAB-185, an antibody therapy investigated for COVID-19, and SAB-176, an influenza-focused therapeutic. Founded in 2014, SAB Biotherapeutics is headquartered in Sioux Falls, South Dakota. The company became publicly traded on Nasdaq in 2021 following a business combination with Big Cypress Acquisition Corp. Its work has primarily centered on developing therapies for markets in the United States, with research and clinical activities conducted in collaboration with academic, government and industry partners.View SAB Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsC.H. Robinson Bets Its AI Story on RXO—But the Market Isn't SoldApplied Digital’s Hidden Moat Could Unlock Massive Upside Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
